The Acu-Corona 2.0 test, which is based on detecting two genes of the Covid-19 virus, Rdrp and E, has been independently validated through the Proficiency Testing program for SARS CoV-2 implemented by College of American Pathologists (CAP).
Q&M Dental Group announced on September 15, that its 51%-owned subsidiary Acumen Diagnostics has obtained the Healthcare Institution License issued by the Ministry of Health to offer clinical laboratory testing services for the SARS CoV-2 RNA.
Acumen will use its proprietary SARS CoV-2 RT-PCR test kit, Acu-Corona 2.0 to provide testing services. The test kit received Singapore Health Sciences Authority’s (HSA) Provisional Authorisation for clinical use in March 2020.
